Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Google Plus   Investorideas is on Youtube   Investorideas is on tumblr   Investorideas is on LinkedIn



BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory


Featured biotech stocks

Aethlon Medical, Inc.

(OTCQB:AMED)

Aethlon Medical, Inc. (OTCQB:AMED) creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. www.aethlonmedical.com

Featured biotech stocks

Vycor Medical Inc.

(OTC: VYCO)

Vycor Medical Inc. (OTC:VYCO) is a publicly traded company, dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue. www.vycormedical.com/

Featured biotech product

Aethlon Hemopurifier®
www.aethlonmedical.com

Investorideas.com featured company product - Aethlon Hemopurifier®

 

Vycor Medical INc.
ViewSite Brain Access System (VBAS)

Investorideas.com featured company product - ViewSite Brain Access System (VBAS)

Biotech News

Tonix Pharmaceuticals Holding Corp. (TNXP) Addressing Underserved Therapeutic Indications with Three Ongoing Clinical Studies
July 2, 2015 (Investorideas.com stocks newswire) Tonix Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of next-generation medications for disorders of the central nervous system.

Paratek Pharmaceuticals, Inc. (PRTK) Addressing Antibiotic Resistance through Development of New Class of Antibiotics
June 26, 2015 (Investorideas.com stocks newswire) Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.

Cytori Therapeutics, Inc. (CYTX) Establishing Early Presence in Emerging Field of Regenerative Medicine
June 25, 2015 (Investorideas.com stocks newswire) Cytori Therapeutics, Inc. is a biotechnology company developing autologous cell therapies from adipose connective tissue designed to treat a variety of medical conditions.

Media Alert for Vycor Medical, Inc. (OTCQB: VYCO); "Vycor Medical Offers Upside Through Vision Therapy" - Portfolio Guru
Point Roberts WA, NEW YORK, NY - June 25, 2015 (Investorideas.com Newswire) - Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a media alert for Vycor Medical, Inc (OTCQB:VYCO) and its NovaVision Vision Restoration Therapy.

Opportunities in Cancer Immunotherapy Throttle Up: George Zavoico of JonesTrading
June 25, 2015 (Investorideas.com stocks newswire) Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick?

Breaking Medical Technology News; Vycor (OTCQB:VYCO) Announces Commercial Release of Its NovaVision Web Deliverable Therapy Suite
BOCA RATON, Florida - June 25, 2015 (Investorideas.com Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the commercial release of its Internet-delivered therapy suite in the U.S.

A Clear Vision for a Turnaround: Ron Najafi of NovaBay Pharmaceuticals
June 24, 2015 (Investorideas.com stocks newswire) What a difference just nine months can make. NovaBay Pharmaceuticals Inc. has a materially derisked business strategy with new products coming rapidly to market, big-time distribution partners in place and new shareholders embracing the stock following a drug trial disappointment in mid-August 2014.

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces $6 Million Equity Investment
SAN DIEGO - June 24, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that it entered into a definitive $6 million stock purchase agreement.

Video Alert: Vycor Medical, Inc. (OTCQB:VYCO) NovaVision Vision Restoration Therapy
Point Roberts, WA, NEW YORK, NY - June 18, 2015 (Investorideas.com Newswire) - Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a video alert for Vycor Medical, Inc (OTCQB:VYCO) featuring its NovaVision Vision Restoration Therapy.

Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners
June 17, 2015 (Investorideas.com stocks newswire) The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech News from Marketwired

InvestorIdeas-Biotech 

Subscribe to Biotech News


Stock Quotes

Stock Quotes

Sign Up

Sign Up for Investing Ideas & Stock Alerts

Email:

www.Investorideas.com

Biotech/ Pharma Stock Directory

Preview

Aastrom Biosciences, Inc. ( NasdaqCM: ASTM ) is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI(TM), a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

ABBOTT LABORATORIES ( NYSE: ABT ) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.

Ablynx ( Brussels: ABLX.BR ) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease.

Acadia Pharmaceuticals Inc. ( NasdaqGS: ACAD ) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, for which we have reported positive Phase III trial results in Parkinson's disease psychosis and which has the potential to be the first drug approved in the United States for this disorder. We are currently completing NDA-enabling clinical and manufacturing activities for pimavanserin and are planning to submit an NDA with the FDA near the end of 2014. Pimavanserin is also in Phase II development for Alzheimer's disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two preclinical programs directed at Parkinson's disease and other neurological disorders. All product candidates are small molecules that emanate from internal discoveries.

Access Pharmaceuticals, Inc. ( OTC:ACCP ) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access developed MuGard and ProctiGard and is developing multiple follow-on products. Access also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.

Acorda Therapeutics, Inc. ( NasdaqGS:ACOR ) is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders. Acorda markets three FDA-approved therapies including: AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure.

See the full biotech stocks directory and login as a member or access as a PDF

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.